PureTech Health (NASDAQ:PRTC) Shares Gap Up – What’s Next?

Shares of PureTech Health plc (NASDAQ:PRTC) gapped up before the market opened on Monday . The stock had previously closed at $20.35, but opened at $22.73. PureTech Health shares last traded at $23.12, with a volume of 11,986 shares traded.

Wall Street Analyst Weigh In

PRTC has been the topic of a number of research reports. Leerink Partnrs upgraded shares of PureTech Health to a “strong-buy” rating in a research report on Monday, September 9th. Leerink Partners assumed coverage on shares of PureTech Health in a report on Monday, September 9th. They set an “outperform” rating and a $45.00 price objective on the stock.

PureTech Health Trading Down 1.6 %

The company has a fifty day moving average price of $21.24 and a 200 day moving average price of $22.42.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in PureTech Health stock. Birch Hill Investment Advisors LLC bought a new stake in shares of PureTech Health plc (NASDAQ:PRTC) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned about 1.26% of PureTech Health as of its most recent SEC filing. Institutional investors and hedge funds own 0.04% of the company’s stock.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.